The Food and Drug Administration is getting closer to welcoming a new commissioner, as a Senate panel voted Tuesday to advance the nomination of Dr. Stephen Hahn.
The U.S. Senate Committee on Health, Education, Labor & Pensions voted 18-5 to push Hahn’s nomination ahead to a full Senate vote.
Hahn, a cancer specialist and medical executive at the MD Anderson Cancer Center in Houston, was nominated by President Donald Trump to lead the FDA last month.
With Republicans holding the majority in the Senate, Hahn will almost certainly sail through, but a full Senate vote has yet to be scheduled. The New York Times reported that Tennessee Sen. Lamar Alexander, the chairman of the health committee, is hopeful that a vote will be held by the end of this year.
Following last month’s nomination, Alexander gave an enthusiastic endorsement of Hahn.
“I had an excellent meeting with Dr. Hahn and believe he is well-qualified to lead the FDA. As an oncologist, Dr. Hahn knows firsthand the importance of bringing new, lifesaving drugs and devices quickly through the regulatory process as well as the need for innovation for patients with debilitating and chronic pain. As a successful chief executive, he will